Posted by
The Psychopharmacology of Depression: Strategies, Formulations, and Future Implications

The Psychopharmacology of Depression: Strategies, Formulations, and Future Implications

With well over two dozen traditional antidepressants available in the US, and an ever-growing list of other psychotropic compounds with apparent antidepressant properties, pharmacological options for treating clinical depression today are broad and vast. However, recent findings suggest that the magnitude of efficacy for most antidepressants compared with placebo may be more modest than previously […]

Posted by
Robert Pollack, MD Certified in Spravato REMS

Robert Pollack, MD Certified in Spravato REMS

Robert Pollack, MD has been certified in the Restrictive Program called Spravato REMS (Risk Evaluation and Mitigation Strategy) for the administration and monitoring of Spravato, the newly released Intranasal formulation of Esketamine for the treatment of TRD (Treatment Resistant Depression). Janssen announced that they received FDA approval for this medication February 5 , 2019. For […]

Posted by
In scathing ruling, judge rips insurer for putting ‘bottom line’ over patients’ health

In scathing ruling, judge rips insurer for putting ‘bottom line’ over patients’ health

In a scathing decision, a federal judge blasted a subsidiary of the nation’s largest insurance company for focusing on the “bottom line as much or more” than patients’ health, saying the insurer illegally denied treatment to thousands of people. The judge also slammed the company’s medical directors for being “deceptive” under oath.US Chief Magistrate Judge […]

Posted by
FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic

FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic

For Immediate Release March 5, 2019 Release The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Because of the risk of serious adverse outcomes resulting […]

Posted by

Neuroplasticity and the next wave of antidepressant strategies

Abstract Depression is a common chronic psychiatric disorder that is also often co-morbid with numerous neurological and immune diseases. Accumulating evidence indicates that disturbances of neuroplasticity occur with depression, including reductions of hippocampal neurogenesis and cortical synaptogenesis. Improper trophic support stemming from stressor-induced reductions of growth factors, most notably brain derived neurotrophic factor (BDNF), likely […]

Posted by
2019 Clinical TMS Society Annual Meeting

2019 Clinical TMS Society Annual Meeting

See you there! PASWFL is excited to be attending the Clinical TMS Society Annual Meeting in Vancouver, BC. We are excited to bring you the 2019 Clinical TMS Society Annual Meeting. Over the last 6 years, our meeting has quadrupled in size as over 532 attendees joined us in 2018. We look forward to another great […]

Posted by
FDA panels back intranasal esketamine for refractory depression

FDA panels back intranasal esketamine for refractory depression

Each disposable intranasal delivery device contains 28 mg esketamine; it will come in prepackaged units of one, two, or three devices to deliver the prescribed doses of 28 mg, 56 mg, or 84 mg, respectively. The device does not require priming and, after use, contains only about 30 microliters of residual medication. Its interlocking design, […]

Posted by
FDA Committees Vote on Esketamine Nasal Spray for Treatment-Resistant Depression

FDA Committees Vote on Esketamine Nasal Spray for Treatment-Resistant Depression

The Food and Drug Administration (FDA)’s Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee voted in favor (14 yes, 2 no, 1 abstain) of the approval of esketamine nasal spray (Spravato; Janssen) for the treatment of adult patients with treatment-resistant depression (TRD). The decision was based on data from five Phase […]

Posted by
Esketamine Evaluated in MDD Patients at Imminent Risk for Suicide

Esketamine Evaluated in MDD Patients at Imminent Risk for Suicide

Janssen announced new findings from a Phase 2 study evaluating esketamine nasal spray in patients with major depressive disorder who were at imminent risk for suicide. The findings were published in the American Journal of Psychiatry. Esketamine nasal spray is an investigational glutamate receptor modulator that is thought to help restore synpatic connections in brain cells in patients […]

Posted by
Intranasal Esketamine Evaluated in Treatment-Resistant Depression

Intranasal Esketamine Evaluated in Treatment-Resistant Depression

(HealthDay News) — Esketamine seems to be efficacious and safe for patients with treatment-resistant depression (TRD), according to a study published online Dec. 27 in JAMA Psychiatry. Ella J. Daley, M.D., from Janssen Research & Development LLC in Titusville, N.J., and colleagues conducted a phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study to examine the efficacy, […]